The evolving place of incretin-based therapies in type 2 diabetes - Wikidata - wikimedia - TriplyDB

The evolving place of incretin-based therapies in type 2 diabetes

The evolving place of incretin-based therapies in type 2 diabetes

http://www.wikidata.org/entity/Q33866808

about

Recent advances in gut nutrient chemosensing Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors Clinical therapeutic strategies for early stage of diabetic kidney disease.The effects of glucose-lowering therapies on diabetic kidney disease Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Obesity and type 2 diabetes: which patients are at risk?Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell surface expression.Dipeptidyl peptidase 4 serum activity and concentration are increased in women with polycystic ovary syndrome.Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

P2860

Q26830947-A415E2E5-777C-46D2-A7CB-C544B9288057 Q26851381-6CEC27A7-1EAD-43F8-A9F3-B882B2A2907B Q30363683-5C5067FD-0BDC-46DB-A97F-C8E3710EAA39 Q33583220-44DE3296-760A-4F28-B247-EA94A3D4D768 Q37929159-F98F895F-55C9-43E4-BFF4-0415E43FCE47 Q37954693-717AF36B-45E9-40F5-A341-1619034C2D2A Q37965613-B1C89EAE-F68B-448F-8A84-485195AED526 Q38042110-D3CBB660-B17F-4397-997D-F26353007452 Q41877149-65CCBB0E-6DF2-4899-ACC0-DEE2AF840A13 Q43167212-FE3E0EEA-F1A6-404F-BDB6-9D47B18500C3 Q47670005-201B6494-E149-41EB-82F3-0F6663ECC5B1 Q55340870-03B86C6E-23F5-4176-8FA4-04C5EF728E9A

P2860

The evolving place of incretin-based therapies in type 2 diabetes

http://www.wikidata.org/entity/Q33866808

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The evolving place of incretin-based therapies in type 2 diabetes

@ast

The evolving place of incretin-based therapies in type 2 diabetes

@en

type

label

The evolving place of incretin-based therapies in type 2 diabetes

@ast

The evolving place of incretin-based therapies in type 2 diabetes

@en

prefLabel

The evolving place of incretin-based therapies in type 2 diabetes

@ast

The evolving place of incretin-based therapies in type 2 diabetes

@en

P1433

Q33866808-71F43842-9057-4DF0-8258-53778ECDCBD2

P1476

Q33866808-B92B66E4-23BA-4822-9433-0EA61554771F

P2860

Q33866808-043A2674-42B3-41E7-BE16-C7EE4FC7A257

Q33866808-0BF283EB-D3A4-4766-AD2C-488ABA0F2DC4

Q33866808-0D5D9DB5-DA1E-4229-8AEB-1256E269D34C

Q33866808-0E13C7E5-FCEB-4543-9479-3CC513EBB058

Q33866808-1BADA6B3-AC53-46E2-93A2-23E9FC87BE84

Q33866808-1CD5C7A4-E4F8-4871-9B58-C4281D61BA5D

Q33866808-1D6C2CE7-CDE0-43F5-AED9-EFFB907C2C48

Q33866808-1E990FCE-E56F-445A-AAB2-2C8511A38AFB

Q33866808-1ED62104-CE3E-467D-86F5-F509D5219410

Q33866808-233DE891-D6D7-4B55-A471-3A4580BC52EB

P2888

Q33866808-0845D3DE-3DC9-49A1-9FE7-AAF23BE98271

P304

Q33866808-931FA35F-B179-40B5-B34D-BAD52F7EC698

P31

Q33866808-A01912CD-6D9A-4736-BE7D-F3D812A510EA

Q33866808-ABF0F040-C5A0-4925-9472-8D94667AC2F0

P356

Q33866808-8A45AD9A-4910-4152-9CF8-7D108F7208DF

P433

Q33866808-EB67D77C-1C93-4E36-954A-DDAD4EF575EB

P478

Q33866808-2694CB77-3369-4483-ACAE-06201E3FD01B

P50

Q33866808-2B261FEE-C8A9-4EB2-9B86-70D5DCBBE1FF

P577

Q33866808-6B6FD9CF-35CA-40F9-9FBE-7D1A7BD9CC18

Q33866808-A82FB1CA-C8FC-4749-9B1C-170F86C3E0E5

P5875

Q33866808-C5D01DA6-52ED-42B3-B9A0-0D4426FFF465

P6179

Q33866808-A03C1656-7C0D-4B49-87BE-00920603F5C9

P698

Q33866808-4B8A0D1B-301A-4DC9-9DB8-8B83987A6ED6

P921

Q33866808-3545AE8F-A557-4D32-9EAD-52B19BF4EBBC

Q33866808-6FEDAC9F-8FFA-4771-80B9-EE6578D2EB97

Q33866808-B6D699FC-BD4C-4844-9136-4510A2C383EC

Q33866808-FF462D16-9247-46B3-B640-3391E981E971

P932

Q33866808-52CED361-AFBE-4A70-AF77-AD0B9A861691

P356

S00467-009-1435-Z

P1433

Pediatric Nephrology

P1476

The evolving place of incretin-based therapies in type 2 diabetes

@en

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Effects of intensive glucose lowering in type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Biology of incretins: GLP-1 and GIP

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.

P2888

s00467-009-1435-z

P304

1207-1217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-009-1435-Z

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Baptist Gallwitz

P577

2010-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41405803

http://www.w3.org/2001/XMLSchema#string

P6179

1036138677

http://www.w3.org/2001/XMLSchema#string

P698

20130920

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

mechanism of action

maturity-onset diabetes of the young

P932

2874027

http://www.w3.org/2001/XMLSchema#string